Trial Profile
A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trebananib (Primary)
- Indications Bone metastases; CNS cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 27 Jul 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 30 Sep 2016 Status changed from active, no longer recruiting to completed.
- 28 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Oct 2016, according to ClinicalTrials.gov record.